To the editor Transfusion-related acute lung injury (TRALI) is among the leading causes of transfusion-related morbidity and mortality. Over the past 20 years, insight into TRALI pathogenesis has resulted in implementation of preventive strategies both from the transfusion medicine/blood bank and clinical settings. Based on this accumulated clinical and basic science knowledge, a panel of 10 international experts on TRALI, including two members with haemovigilance expertise, used the Delphi approach to develop a recently published redefinition of TRALI by modifying the widely used 2004 TRALI Canadian Consensus Conference (CCC) definition (Table 1) 
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The updated TRALI definition/classification scheme along with the rationale for the changes has now been published (Table 2) [2] . The main modifications are: (1) TRALI has been separated into two types. TRALI type I applies to cases without an ARDS risk factor and TRALI type II to cases with an ARDS risk factor or with mild pre-existing ARDS. Notably, the presence of either an ARDS risk factor or mild ARDS does not exclude the diagnosis of TRALI as it did under the old definition; (2) the term ''possible TRALI'' has been dropped; (3) Cases with an ARDS risk factor which meet ARDS diagnostic criteria and where respiratory deterioration over the 12 h prior to transfusion implicates the risk factor as causative should be classified as ARDS rather than TRALI type II; (4) The 2012 updated ARDS consensus definition (referred to as the BER-LIN ARDS definition) has been evaluated for its relevance to TRALI and essential updates (including updating the list of commonly accepted ARDS risk factors and expanding the methods for diagnosing hydrostatic pulmonary edema) have been incorporated into the new TRALI definition.
More broadly, the Delphi panel recommended that all pulmonary complications after blood transfusion should be reported to the transfusion service and then categorized (either by the transfusion service, a hospital transfusion committee or a haemovigilance system) into one of several categories: TRALI (type I or type II), ARDS, transfusion associated circulatory overload (TACO), TRALI/TACO cannot distinguish, or an alternate diagnosis. Importantly, the panel reaffirmed that TRALI remains a clinical diagnosis and does not require detection of cognate leukocyte antibodies, though it did recommend that these data be captured through a haemovigilance reporting system. Future research directions have been identified and include identifying the mechanism behind the onset of TRALI in the absence of cognate leukocyte antibodies. Furthermore, the panel is working on developing a universal reporting form for post-transfusion pulmonary complications including suspected TRALI.
We believe that the modified TRALI definition is of substantial importance and needs to be widely disseminated and discussed. To this end, the panel has submitted similar letters to the editor of several important transfusion and hemovigilance journals [3, 4] . In addition, a revised surveillance definition of Transfusion Associated Circulatory Overload (TACO) has recently been published [5] . We hope that these new definitions will contribute to an enhanced level of reporting and a more accurate classification of respiratory complications associated with blood transfusion. In the presence of an alternative risk factor for ALI Use objective evaluation when LAH is suspected (imaging e.g. echocardiography, or invasive measurement using e.g. pulmonary artery catheter) c Onset of pulmonary symptoms (e.g. hypoxemia-lower P/F ratio or SpO 2 ) should be within 6 h of end of transfusion. The additional findings needed to diagnose TRALI (pulmonary edema on a lung imaging study and determination of lack of substantial LAH) would ideally be available at the same time but could be documented up to 24 h after TRALI onset 
